Targeted Oncology is a pragmatic tool for all physicians and scientists committed to oncology and cancer research.

Recently, a better understanding of the genetics and biology of cancer have provided important clues to the pathology of the disease and to new therapeutic strategies. Innovative treatments, including small molecule inhibitors and biologicals targeting oncogenic pathways and immune checkpoints have emerged and are currently revolutionizing the way we treat cancer patients. Despite these breakthroughs, significant work remains in understanding these new compounds and identifying markers of treatment success.

Targeted Oncology focuses on Original Research Articles on both pre-clinical and clinical aspects of molecularly targeted agents, and on comprehensive narrative Review Articles discussing clinically established as well as emerging agents and pathways. The journal also publishes Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement, and Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.

Targeted Oncology offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.

There are no publication charges for standard publishing in Targeted Oncology; the journal offers the option of Open Access publication via Springer Open Choice (article processing charge €3,060 / US$3,860). Please click on the link below under ‘Publishing model’ for further information about this service.

Journal information

Editor-in-Chief
  • Martin Chopra
Publishing model
Hybrid. Open Access options available

Journal metrics

3.683 (2018)
Impact factor
3.118 (2018)
Five year impact factor
14 days
Submission to first decision
102 days
Submission to acceptance
87,689 (2019)
Downloads

Latest articles

This journal has 72 open access articles

About this journal

Electronic ISSN
1776-260X
Print ISSN
1776-2596
Abstracted and indexed in
  1. CNKI
  2. EBSCO Biomedical Reference Collection
  3. EBSCO CINAHL
  4. EBSCO Discovery Service
  5. EMBASE
  6. Gale
  7. Gale Academic OneFile
  8. Gale InfoTrac
  9. Google Scholar
  10. INIS Atomindex
  11. Institute of Scientific and Technical Information of China
  12. Japanese Science and Technology Agency (JST)
  13. Journal Citation Reports/Science Edition
  14. Medline
  15. Naver
  16. OCLC WorldCat Discovery Service
  17. ProQuest Central
  18. ProQuest Consumer Health
  19. ProQuest Health & Medical Collection
  20. ProQuest Health Research Premium Collection
  21. ProQuest Medical Database
  22. ProQuest Nursing & Allied Health Database
  23. ProQuest Pharma Collection
  24. ProQuest-ExLibris Primo
  25. ProQuest-ExLibris Summon
  26. Reaxys
  27. SCImago
  28. SCOPUS
  29. Science Citation Index Expanded (SciSearch)
  30. Semantic Scholar
Copyright information

Rights and permissions

Springer policies

© Springer Nature Switzerland AG